Squarepoint
ITRM

Squarepoint’s Iterum Therapeutics ITRM Stock Holding History

Squarepoint’s Portfolio ITRM Stock Details ITRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-443,972
Closed -$297K – 4567
2025
Q3 		$297K Sell
443,972
-12,889
-3% -$10.1K ﹤0.01% 3679
2025
Q2 		$455K Buy
+456,861
New +$476K ﹤0.01% 3355
2022
Q3 		– Sell
-2,963
Closed -$9K – 3197
2022
Q2 		$9K Sell
2,963
-8
-0.3% -$30 ﹤0.01% 2795
2022
Q1 		$16K Sell
2,971
-333
-10% -$1.93K ﹤0.01% 2722
2021
Q4 		$19K Sell
3,304
-196
-6% -$1.51K ﹤0.01% 3085
2021
Q3 		$29K Buy
3,500
+1,808
+107% +$22.3K ﹤0.01% 2809
2021
Q2 		$59K Sell
1,692
-1,654
-49% -$35.9K ﹤0.01% 3092
2021
Q1 		$71K Buy
+3,346
New +$79.7K ﹤0.01% 2958

Other funds holding ITRM

AF
Apollon Financial Mount Pleasant, South Carolina $848M AUM 27.31% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
AW
Alchemi Wealth Essex, Connecticut $213M AUM
CAPTRUST Financial Advisors
CAPTRUST Financial Advisors Raleigh, North Carolina $65.5B AUM 24.25% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
GWP
Gen-Wealth Partners Zeeland, Michigan $360M AUM 27.44% 1-Year Est. Return
KF
Krilogy Financial St. Louis, Missouri $3.38B AUM 30.57% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
GSC
Ground Swell Capital Folly Beach, South Carolina $92.6M AUM 41.64% 1-Year Est. Return
SA
Sanctuary Advisors Indianapolis, Indiana $21.6B AUM 28.31% 1-Year Est. Return

Squarepoint's ITRM Position: Q4 2025 in Review

Squarepoint sold out of Iterum Therapeutics (ITRM) in Q4 2025, closing a stake of 443,972 shares — an estimated $297K sold.

Squarepoint first reported a position in ITRM in Q1 2021 and held it in 8 quarters. The position peaked at $455K in Q2 2025. 20 funds tracked by Wall St. Rank hold ITRM as of Q4 2025.

  • Squarepoint reported no remaining Iterum Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Squarepoint sold 443,972 Iterum Therapeutics shares in Q4 2025, an estimated $297K.
  • Squarepoint first reported a position in Iterum Therapeutics in Q1 2021 and held it in 8 quarters.
  • Squarepoint's Iterum Therapeutics position peaked at $455K in Q2 2025.
  • 20 funds tracked by Wall St. Rank held Iterum Therapeutics as of Q4 2025.

Based on Squarepoint's 13F filing for Q4 2025, filed 13 Feb 2026.